ALK and non-small cell lung carcinoma: Although next-generation ALK-TKIs such as alectinib, brigatinib demonstrated superior PFS vs. crizotinib in untreated ALK-positive NSCLC regardless of baseline brain metastases (26–28), the difference in OS of patients who received crizotinib or next-generation ALK-TKIs as first-line therapy is still unknown.